Published in Proc Natl Acad Sci U S A on September 11, 2008
Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov (2010) 5.76
Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol (2011) 3.15
Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med (2010) 2.82
Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci Signal (2011) 2.56
Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev (2010) 2.30
Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell (2009) 1.83
Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci (2009) 1.59
β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res (2013) 1.59
Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure (2012) 1.55
Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX. Structure (2011) 1.54
Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A (2009) 1.53
beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal (2010) 1.45
Ligand-directed signalling at beta-adrenoceptors. Br J Pharmacol (2010) 1.40
Critical Roles of STAT3 in β-Adrenergic Functions in the Heart. Circulation (2015) 1.40
Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. Circ Res (2012) 1.20
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc (2014) 1.18
beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem (2009) 1.17
G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res (2011) 1.15
Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol (2010) 1.11
β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin (2012) 1.10
Targeting G protein coupled receptor-related pathways as emerging molecular therapies. Saudi Pharm J (2013) 1.06
Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. Mol Endocrinol (2014) 1.04
Functional selectivity in adrenergic and angiotensin signaling systems. Mol Pharmacol (2010) 0.99
MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc Res (2015) 0.99
Nuclear GPCRs in cardiomyocytes: an insider's view of β-adrenergic receptor signaling. Am J Physiol Heart Circ Physiol (2011) 0.97
Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci (2011) 0.97
Biased and g protein-independent signaling of chemokine receptors. Front Immunol (2014) 0.96
MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound β(2)-adrenergic receptors. J Cell Biol (2012) 0.96
Adrenergic signaling in heart failure: a balance of toxic and protective effects. Pflugers Arch (2014) 0.94
The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist. PLoS One (2013) 0.91
Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. Cell Signal (2014) 0.91
The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases. Br J Pharmacol (2012) 0.91
β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt. J Mol Cell Cardiol (2014) 0.90
Probing heterotrimeric G protein activation: applications to biased ligands. Curr Pharm Des (2012) 0.89
Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmacol Ther (2014) 0.88
A pharmacological primer of biased agonism. Endocr Metab Immune Disord Drug Targets (2011) 0.86
Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. Biochem Biophys Res Commun (2010) 0.85
β-Arrestin mediates oxytocin receptor signaling, which regulates uterine contractility and cellular migration. Am J Physiol Endocrinol Metab (2010) 0.84
(R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility. Biochem Pharmacol (2013) 0.82
S49G and R389G polymorphisms of the β₁-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways. Physiol Genomics (2013) 0.82
Biased β2 -adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol (2014) 0.82
Induction of cardiac fibrosis by β-blocker in G protein-independent and G protein-coupled receptor kinase 5/β-arrestin2-dependent Signaling pathways. J Biol Chem (2012) 0.81
Airway epithelial epidermal growth factor receptor mediates hogbarn dust-induced cytokine release but not Ca2+ response. Am J Respir Cell Mol Biol (2011) 0.81
Phosphorylation of the deubiquitinase USP20 by protein kinase A regulates post-endocytic trafficking of β2 adrenergic receptors to autophagosomes during physiological stress. J Biol Chem (2015) 0.81
Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention. Clujul Med (2014) 0.80
Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed β₂-adrenergic receptors. Sci Rep (2014) 0.80
β-Arrestin-biased signaling mediates memory reconsolidation. Proc Natl Acad Sci U S A (2015) 0.80
Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev (2015) 0.79
Carvedilol-responsive microRNAs, miR-199a-3p and -214 protect cardiomyocytes from simulated ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol (2016) 0.79
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
Cardiac risk in the treatment of breast cancer: assessment and management. Breast Cancer (Dove Med Press) (2015) 0.78
Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology. Biomol Ther (Seoul) (2017) 0.77
Prevention of skin carcinogenesis by the β-blocker carvedilol. Cancer Prev Res (Phila) (2014) 0.77
Advances in receptor conformation research: the quest for functionally selective conformations focusing on the β2 -adrenoceptor. Br J Pharmacol (2015) 0.76
Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. Front Endocrinol (Lausanne) (2013) 0.76
Conducting the G-protein Coupled Receptor (GPCR) Signaling Symphony in Cardiovascular Diseases: New Therapeutic Approaches. Drug Discov Today Dis Models (2012) 0.76
G Protein-coupled Receptor Biased Agonism. J Cardiovasc Pharmacol (2016) 0.75
Phosphorylation of Src by phosphoinositide 3-kinase regulates beta-adrenergic receptor-mediated EGFR transactivation. Cell Signal (2016) 0.75
β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci U S A (2016) 0.75
Physiological implications of biased signaling at histamine H2 receptors. Front Pharmacol (2015) 0.75
A Practical Guide to Approaching Biased Agonism at G Protein Coupled Receptors. Front Neurosci (2017) 0.75
Partial agonist and biased signaling properties of the synthetic enantiomers J113863/UCB35625 at chemokine receptors CCR2 and CCR5. J Biol Chem (2016) 0.75
Identification of gene signatures regulated by carvedilol in mouse heart. Physiol Genomics (2015) 0.75
Alpha1a-Adrenoceptor Genetic Variant Triggers Vascular Smooth Muscle Cell Hyperproliferation and Agonist Induced Hypertrophy via EGFR Transactivation Pathway. PLoS One (2015) 0.75
Agonist binding to β-adrenergic receptors on human airway epithelial cells inhibits migration and wound repair. Am J Physiol Cell Physiol (2015) 0.75
Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model. SAGE Open Med (2017) 0.75
β1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via β3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. J Am Coll Cardiol (2017) 0.75
Cardiac GPCR-mediated EGFR transactivation: impact and therapeutic implications. J Cardiovasc Pharmacol (2017) 0.75
Transduction of receptor signals by beta-arrestins. Science (2005) 9.87
Beta-arrestins and cell signaling. Annu Rev Physiol (2007) 8.65
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ (2004) 7.92
Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science (1999) 7.57
EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature (2000) 7.03
G protein-coupled receptor kinases. Annu Rev Biochem (1998) 5.53
beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J Biol Chem (2005) 4.91
Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci U S A (2001) 4.56
beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol (2000) 4.29
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
beta-adrenergic receptor blockade in chronic heart failure. Circulation (2000) 3.43
Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest (2007) 3.15
Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem (2004) 3.07
Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J (1975) 2.71
Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol (2006) 2.69
Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem (2005) 2.64
Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A (2001) 2.58
Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A (2005) 2.53
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.95
Assembly of an A kinase-anchoring protein-beta(2)-adrenergic receptor complex facilitates receptor phosphorylation and signaling. Curr Biol (2000) 1.90
Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation (2000) 1.87
Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J Biol Chem (2004) 1.86
Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem (2007) 1.85
beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem (2004) 1.75
Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem (2003) 1.66
Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci (1995) 1.60
Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol (2003) 1.52
Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest (2007) 1.44
Site of action of beta-ligands at the human beta1-adrenoceptor. J Pharmacol Exp Ther (2005) 1.36
Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol Metab (2000) 1.23
Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther (2001) 1.16
EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists. Sci STKE (2000) 1.15
Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.12
Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation (2003) 1.08
The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol (1988) 1.03
Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol (1985) 0.97
Are we misunderstanding beta-blockers. Int J Cardiol (2007) 0.97
Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci (2002) 0.96
Effect of the counter-anion type and concentration on the liquid chromatography retention of beta-blockers. J Chromatogr A (2002) 0.92
Effects of single doses of alprenolol and two cardioselective beta-blockers (H 87-07 and H 93-26) on exercise-induced angina pectoris. Eur J Clin Pharmacol (1974) 0.84
Agonist-specific activation of the beta2-adrenoceptor/Gs-protein and beta2-adrenoceptor/Gi-protein pathway in adult rat ventricular cardiomyocytes. Br J Pharmacol (2006) 0.80
Carvedilol, a nonselective beta-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Transl Res (2007) 0.80
Do recent operational studies indicate that a single state model is no longer applicable to G protein-coupled receptors? Ann N Y Acad Sci (1997) 0.80
Chiral cardiovascular drugs: an overview. Am J Ther (2005) 0.78
Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science (2002) 18.89
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest (2007) 3.15
New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell (2006) 3.11
Beta-arrestin-mediated localization of smoothened to the primary cilium. Science (2008) 3.10
Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res (2004) 2.98
Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab (2005) 2.82
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem (2007) 2.51
Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A (2005) 2.48
beta-arrestins: traffic cops of cell signaling. Curr Opin Cell Biol (2004) 2.40
Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci U S A (2004) 2.34
Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest (2006) 2.33
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Drosophila as a model for the identification of genes causing adult human heart disease. Proc Natl Acad Sci U S A (2006) 2.22
An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A (2005) 2.18
Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci U S A (2009) 2.13
Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol (2011) 2.08
Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc Natl Acad Sci U S A (2008) 2.06
Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A (2006) 2.01
Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat Cell Biol (2005) 2.00
Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs. Cell Metab (2010) 1.98
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest (2006) 1.92
Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther (2010) 1.87
Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A (2009) 1.84
beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest (2009) 1.79
Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol (2003) 1.78
beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem (2004) 1.75
Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation (2003) 1.70
Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem (2003) 1.66
Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci Signal (2009) 1.66
β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res (2012) 1.66
A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. Nature (2011) 1.64
TRPC1 channels are critical for hypertrophic signaling in the heart. Circ Res (2009) 1.64
S-nitrosylation of beta-arrestin regulates beta-adrenergic receptor trafficking. Mol Cell (2008) 1.63
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther (2013) 1.62
β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res (2013) 1.59
Redefining heart failure: the utility of genomics. J Am Coll Cardiol (2006) 1.52
Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol (2014) 1.51
Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest (2003) 1.47
Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta (2007) 1.45
beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal (2010) 1.45
Tnni3k modifies disease progression in murine models of cardiomyopathy. PLoS Genet (2009) 1.44
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem (2003) 1.43
Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol (2004) 1.41
Pressure overload selectively up-regulates Ca2+/calmodulin-dependent protein kinase II in vivo. Mol Endocrinol (2003) 1.40
Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol (2002) 1.40
Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol (2002) 1.38
beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation. J Cell Biol (2010) 1.35
Nicotine is a developmental neurotoxicant and neuroprotectant: stage-selective inhibition of DNA synthesis coincident with shielding from effects of chlorpyrifos. Brain Res Dev Brain Res (2003) 1.34
Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol (2005) 1.33
Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants. Hum Mol Genet (2007) 1.28
Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol Genomics (2003) 1.28
G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res (2004) 1.27
Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther (2006) 1.25
When 7 transmembrane receptors are not G protein-coupled receptors. J Clin Invest (2005) 1.24
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail (2011) 1.24
Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. Circulation (2002) 1.21
Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. J Biol Chem (2004) 1.20
GIPC interacts with the beta1-adrenergic receptor and regulates beta1-adrenergic receptor-mediated ERK activation. J Biol Chem (2003) 1.20
Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. Am J Physiol Heart Circ Physiol (2006) 1.19
Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood (2007) 1.19
Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res (2011) 1.19
Beta-arrestin-mediated signaling regulates protein synthesis. J Biol Chem (2008) 1.18
Tradition, tradition. J Clin Invest (2012) 1.18
Inconsistencies between actual and estimated blood alcohol concentrations in a field study of college students: do students really know how much they drink? Alcohol Clin Exp Res (2005) 1.17
beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem (2009) 1.17
Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol (2009) 1.17
Network integration of the adrenergic system in cardiac hypertrophy. Cardiovasc Res (2004) 1.16
β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol (2012) 1.15
Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. Circulation (2005) 1.14
Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation (2005) 1.14
Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol (2010) 1.11
PKA-mediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching. Cell Signal (2004) 1.11
Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy. Hum Mol Genet (2003) 1.11
Distinct effects of tafazzin deletion in differentiated and undifferentiated mitochondria. Mitochondrion (2008) 1.10
Physiologic and cardiac roles of beta-arrestins. J Mol Cell Cardiol (2008) 1.04
Cardiac micro-computed tomography for morphological and functional phenotyping of muscle LIM protein null mice. Mol Imaging (2007) 1.03
First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol (2013) 1.03
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail (2012) 1.03
QTL mapping in a mouse model of cardiomyopathy reveals an ancestral modifier allele affecting heart function and survival. Mamm Genome (2005) 1.03
A role for the thromboxane receptor in L-NAME hypertension. Am J Physiol Renal Physiol (2008) 1.02